MedWatch

CEO left million-dollar company in favor of clinical-stage biotech firm

The CEO in Danish Specific Pharma has stepped down from her position to join a promising biotech firm and potential Leo Pharma-rival.

Danish biotech firm MC2 Therapeutics is approaching a potential breakthrough after announcing positive data in phase II- and phase III clinical trials with candidates against dry eyes and plaque psoriasis. The company expects to launch the psoriasis candidate in the US and then Europe in 2020/2021.

Next development phase requires commercial reinforcement. With the eye drop, MC2 Therapeutics aims to compete with the companies Allergans Restasis and Santen Therapeutics Ikervis, and the candidate against plaque psoriasis could be a potential rival to Danish Leo Pharma.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier